Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

The number of people with glaucoma worldwide in 2010 and 2020.

Quigley HA, Broman AT.

Br J Ophthalmol. 2006 Mar;90(3):262-7.

2.

The rising cost of glaucoma drugs in Ireland 1996-2003.

Knox FA, Barry M, McGowan B, O'Brien C.

Br J Ophthalmol. 2006 Feb;90(2):162-5.

3.

Persistence and adherence with topical glaucoma therapy.

Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM.

Am J Ophthalmol. 2005 Oct;140(4):598-606.

PMID:
16226511
4.

Side-effect profile of brimonidine tartrate in children.

Al-Shahwan S, Al-Torbak AA, Turkmani S, Al-Omran M, Al-Jadaan I, Edward DP.

Ophthalmology. 2005 Dec;112(12):2143. Epub 2005 Oct 12.

PMID:
16225927
5.

Medical therapy of glaucoma.

Singh A.

Ophthalmol Clin North Am. 2005 Sep;18(3):397-408, vi. Review.

PMID:
16054997
6.

Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.

van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH.

Ophthalmology. 2005 Jul;112(7):1177-85.

PMID:
15921747
7.

Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.

Camras CB, Sheu WP; United States Latanoprost-Brimonidine Study Group.

J Glaucoma. 2005 Apr;14(2):161-7.

PMID:
15741820
8.

The effect of combination pharmacotherapy on the prescription trends of glaucoma medications.

Kaiserman I, Kaiserman N, Nakar S, Vinker S.

J Glaucoma. 2005 Apr;14(2):157-60.

PMID:
15741819
9.

Tales of two drugs.

Neufeld AH.

J Glaucoma. 2005 Feb;14(1):1-2. No abstract available.

PMID:
15650596
10.

Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.

Chou SY, Chou CK, Kuang TM, Hsu WM.

Eye (Lond). 2005 Jul;19(7):784-7.

PMID:
15359238
13.
14.

Role of alpha-2 agonists in neuroprotection.

Wheeler L, WoldeMussie E, Lai R.

Surv Ophthalmol. 2003 Apr;48 Suppl 1:S47-51. Review.

PMID:
12852434
15.

Medical therapy cost considerations for glaucoma.

Fiscella RG, Green A, Patuszynski DH, Wilensky J.

Am J Ophthalmol. 2003 Jul;136(1):18-25.

PMID:
12834665
16.
17.

The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial.

Inan UU, Ermis SS, Yücel A, Oztürk F.

Acta Ophthalmol Scand. 2003 Apr;81(2):155-60.

18.
19.

Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.

Liu CJ, Ko YC, Cheng CY, Chiu AW, Chou JC, Hsu WM, Liu JH.

Ophthalmology. 2002 Dec;109(12):2241-7.

PMID:
12466165
20.

Eyelash hypertrichosis induced by topical latanoprost: 6-month follow-up study.

Stecchi G, Saccucci S, Molinari S, De Gregorio F.

Acta Ophthalmol Scand Suppl. 2002;236:56-7. No abstract available.

PMID:
12390146

Supplemental Content

Support Center